Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

KOR-PED-202 An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis With Moderate-to-Severe Pruritus

NCT06593392 is registered in ClinicalTrials.gov with Vifor Fresenius Medical Care Renal Pharma as lead sponsor.

NCT NCT06593392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06593392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
KOR-PED-202 An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis With Moderate-to-Severe Pruritus
Lead sponsor
Vifor Fresenius Medical Care Renal Pharma
Phase
Phase 2
Overall status
Recruiting
Start date
August 4, 2026
Completion date
August 15, 2029
Enrollment
18 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases, pruritus